Byrne Asset Management LLC Biogen Inc. Transaction History

Byrne Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Jan 29, 2025	BUY	$189.07 - $236.8 $1,890 - $2,368	10 New	10 $1,000
Q3 2024 Jan 28, 2025	BUY	$189.07 - $236.8 $1,890 - $2,368	10 New	10 $1,000
Q4 2023 Jan 29, 2024	SELL	$222.59 - $267.94 $3,116 - $3,751	-14 Reduced 58.33%	10 $2,000
Q3 2023 Oct 31, 2023	BUY	$253.3 - $285.89 $759 - $857	3 Added 14.29%	24 $6,000
Q2 2023 Jul 21, 2023	BUY	$275.25 - $318.06 $5,780 - $6,679	21 New	21 $5,000

993

131M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Byrne Asset Management LLC with notifications on news.